Roche Pharma unveils multiple sclerosis treatment drug Ocrevus in India

New Delhi: Roche Pharma India has launched a drug for the treatment of Multiple Sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of patients grappling with the disease.

The company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).

Read also: Roche Xolair gets USFDA nod for children, adults with one or more food allergies

Medical Dialogues team had earlier reported that Roche's Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) had received Breakthrough Device Designation from the USFDA.

Read also: Roche receives USFDA Breakthrough Device Designation for Multiple Sclerosis test Elecsys NfL